Clopidogrel Resistance

Heart Lung and Circulation

Volumn 16, Issue SUPPL. 3, 2007, Pages

  Oqueli, Ernesto ^a   Hiscock, Martin ^a   Dick, Ronald ^a  

^a EPWORTH HOSPITAL   (Australia)

Author keywords

Adenosine Diphosphate; Clopidogrel; Clopidogrel resistance; Cytochrome P 450 Enzyme System; P2Y12 receptor; Platelet activation; Platelet aggregation; Platelet aggregation inhibitors; Receptors, Purinergic P2; Resistance to drugs

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AR C 69931MX; ATORVASTATIN; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 3A4; FLUINDOSTATIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRASUGREL; PRAVASTATIN; PURINE P2 RECEPTOR; PURINE P2Y12 RECEPTOR; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY STENT; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; EX VIVO STUDY; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; ST SEGMENT; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TICLOPIDINE; TREATMENT FAILURE;

EID: 34547789194     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2007.03.012     Document Type: Review

References (76)

1. Fox K.A.A., Mehta S.R., Peters R., Zhao F., Lakkis N., Gersh B.J., and Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST elevation acute coronary syndrome. The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation 110 (2004) 1202-1208
2. Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M., Lewis B., Natarajan M., Malmberg K., Rupprecht H., Zhao F., and Chrolavicius S. Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
3. The CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
4. Yusuff S., Zhao F., Mehta S.R., Chrolavicius S., Toqnoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
5. Sabatine M.S., Cannon C.P., Gibson M., Lopez-Sendon J., Montalescot G., Theroux P., Claeys M.J., Cools F., Hill K.A., Skene A.M., McCabe C.H., and Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28. N Engl J Med 352 (2005) 1179-1189
6. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., Collins R., and Liu S.L. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. COMMIT collaborative group. Lancet 366 (2005) 1607-1621
7. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, Jacobs AK, Kern MJ, King III SB, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). American Heart Association Web Site. Available at: http://www.americanheart.org.
8. Steinhubl R., Berger P.B., Mann III J.T., Fry E.T.A., DeLago A., Wilmer C., and Topol E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 288 (2002) 2411-2420
9. Gurbel P.A., Bliden K.P., and O'Connor C.M. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
10. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 46 (2006) 277-300
11. Freedman J.E. Molecular regulation of platelet-dependent thrombosis. Circulation 112 (2005) 2725-2734
12. Kleiman N.S. Platelets, the cardiologist, and coronary artery disease: moving beyond aggregation. J Am Coll Cardiol 43 11 (2004) 1989-1991
13. Geiger J., Brich J., Honig-Liedl P., Eigenthaler M., Schanzenbacher P., Herbert J.M., and Walter U. Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 19 (1999) 2007-2011
14. Ding Z., Kim S., Dorsam R.T., Jin J., and Kunapuli P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101 (2003) 3908-3914
15. Geiger J., Teichmann L., Grossmann R., Aktas B., Steigerwald U., Walter U., and Schinzel R. Monitoring of clopidogrel action: comparison of methods. Clin Chem 51 6 (2005) 957-965
16. Conley P.B., and Delaney S.M. Scientific and therapeutics insights into the role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol 10 (2003) 333-338
17. Hechler B., Cattaneo M., and Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost 31 2 (2005) 150-161
18. Clarke T.A., and Waskell L.A. The metabolism of clopidogrel is catalyzed by human cytocrhome P450 3A and is inhibited by atorvatstatin. Drug Metab Dispos 31 1 (2003) 53-59
19. Pereillo J.-M., Maftouh M., Andrieu A., Uzabiaga M.-F., Fedeli O., Savi P., Pascal M., Herbert J.-M., Maffrand J.-P., and Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30 (2002) 1288-1295
20. Bates E.R., Lau W.C., and Bleske B.E. Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation 111 (2005) 2557-2559
21. Giuliano R.P., and Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 46 (2005) 906-919
22. von Beckerath N., Taubert D., Pogatsa-Murray G., Schömig E., Kastrati A., and Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900 mg loading doses of clopidogrel. Results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 112 (2005) 2946-2950
23. Hochholzer W., Trenk D., Frundi D., Blanke P., Fischer B., Andris K., Bestehorn H.-P., Büttner H.-J., and Neumann F.-J. Time dependence of platelet inhibition after a 600 mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
24. Muller I., Besta F., Schultz C., Massberg S., Schönig A., and Gawas M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
25. Gurbel P.A., Bliden K.P., Zaman K.A., Yoho J.A., Hayes K.M., and Tantry U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets study. Circulation 111 (2005) 1153-1159
26. Xiao Z., and Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 43 (2004) 1982-1988
27. Azar R.R., Kassab R., Zoghbi A., Aboujaoude A., El-Osta H., Ghorra P., Germanos M., and Salame E. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C reactive protein in patients with stable coronary artery disease. Am Heart J 151 (2006) 521e1-521e4
28. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
29. Wiviott S.D., and Antman E.M. Clopidogrel resistance. A new chapter in a fast-moving story. Circulation 109 (2004) 3064-3067
30. Guthikonda S., Lev E.I., and Kleinman N.S. Resistance to antiplatelet therapy. Curr Cardiol Reports 7 (2005) 242-248
31. Bates E., and Lau W.C. Controversies in antiplatelet therapy for patients with cardiovascular disease. Circulation 111 (2005) 267-271
32. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
33. Matetzky S., Shenkman B., Guetta V., Schechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., and Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
34. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24 (2004) 1980-1987
35. Michelson A.D. Platelet function testing in cardiovascular disease. Circulation 110 (2004) e489-e493
36. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., and Tantry U.S. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J Am Coll Cardiol 46 (2005) 1827-1832
37. Mclaclan C., Mossop P.J., and Deng Y. Evaluation of clopidogrel resistance. Thromb Res 116 (2005) 451-453
38. Poulsen T.S., Vinholt P., Mickley H., Korsholm L., Kristensen S.R., and Damkier P. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. Basic Clin Pharmacol Toxicol 96 (2005) 103-110
39. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., Lafont A., Camoin L., Walter U., and Eigenthaler M. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Cathet Cardiovasc Intervent 59 (2003) 295-302
40. Wang T.H., Bhatt D.L., and Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27 (2006) 647-654
41. Gawaz M., Neumann F.J., Ott I., Schiessler A., and Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93 (1996) 229-237
42. Serebruany V.L., Malinin A.I., Jerome S.D., Lowry D.R., Morgan A.W., Sane D.C., Tanguay J.-F., Steinhubl S.R., and O'Connor C.M. Effect of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: The Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 146 (2003) 713-720
43. Soffer D., Moussa I., Harjai K.J., Boura J.A., Dixon S.R., Grines C.L., O'Neill W.W., Rubin G.S., and Moses J.W. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?. Cathet Cardiovasc Intervent 59 (2003) 21-25
44. Lepantalo A., Virtanen K.S., Heikkila J., Wartiovaara U., and Lassila R. Limited early antiplatelet effect of 300 mg of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary intervention. Eur Heart J 25 (2004) 476-483
45. Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., Bray P.F., and Kleinman N.S. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
46. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., and Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
47. Kawasaki T., Ozeki Y., Igawa T., and Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low dose aspirin. Stroke 31 (2000) 591-595
48. Clarke T.A., and Waskel L.A. The metabolism of clopidogrel is catalysed by human cytochrome P450 3A and is inhibited by Atorvastatin. Drug Metab Dispos 31 (2003) 53-59
49. Lau W.C., Waskell L.A., Neer C.J., Carville D.G.M., and Bates E.R. The antiplatelet effect of clopidogrel is inhibited by atorvastatin but not by pravastatin. Circulation 102 Suppl. II (2000) 18 pII-429
50. Lau W.C., Waskell L.A., Watkins P.B., Neer C.J., Horowitz K., Hopp A.S., Tait A.R., Carville D.G.M., Guyer K.E., and Bates E.R. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 107 (2003) 32-37
51. Neubauer H., Günesdogan B., Hanefeld C., Spiecker M., and Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J 24 (2003) 1744-1749
52. Mitsios J.V., Papathanasiou A.I., Rodis F.I., Elisaf M., Goudevenos J.A., and Tselepis A.D. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109 (2004) 1335-1338
53. Muller I., Besta F., Shultz C., Zhongyan L., Massberg S., and Gawas M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 108 (2003) 2195-2197
54. Serebruany V.L., Malinin A.I., Callahan K.P., Gurbel P.A., and Steinhubl S.R. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 159 (2001) 239-241
55. Serebruany V.L., Midei M.G., Malinin A.I., Oshrine B.R., Lowry D.R., Sane D.C., Tanguay J.-F., Steinhubl S.R., Berger P.B., O'Connor C.M., and Hennekens C.H. Absence of interaction between atorvastatin or other statins and clopidogrel. Results from the Interaction Study. Arch Intern Med 164 (2004) 2051-2057
56. Vinholt P., Poulsen T.S., Korsholm L., Kristensen S.R., Hallas J., Damkier P., and Mickley H. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost 94 2 (2005) 438-443
57. Gorchakova O., von Beckerath N., Gawaz M., Mocz A., Joost A., Scomig A., and Kastrati A. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 25 (2004) 1898-1902
58. Saw J., Steinhubl S.R., Berger P.B., Kereiakes D.J., Serebruany V.L., Brenan D., Topol E.J., and for the clopidogrel for the reduction of events during observation (CREDO) investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108 (2003) 921-924
59. Wienbergen H., Gitt A.K., Schiele R., Juenger C., Heer T., Meinsenzahl C., Limbourg P., Bossaller C., Senges J., and for the MITRA PLUS Study Group. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 92 (2003) 285-288
60. Lau W.C., Gurbel P.A., Watkins P.B., Neer C.J., Hopp A.S., Carville D.G.M., Guyer K.E., Tait A.R., and Bates E.R. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
61. Michos E.D., Ardehali R., Blumenthal R.S., Lange R.A., and Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin Proc 81 4 (2006) 518-526
62. Fontana P., Dupont A., Gandrille S., Bachelot-Loza C., Reny J.L., Aiach M., and Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108 (2003) 989-995
63. Fontana P., Gaussem P., Aiach M., Fiessinger J.-N., Emmerich J., and Reny J.-L. P2Y12 H2 haplotype is associated with peripheral arterial disease. A case-control study. Circulation 108 (2003) 2971-2973
64. von Beckerath N., von Beckerath O., Koch W., Eichinger M., Schomig A., and Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 16 (2005) 199-204
65. Ajzenberg N., Aubry P., Huisse M.-G., Cachier A., Amara W.E., Feldman L.J., Himbert D., Baruch D., Guillin M.-C., and Steg G. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. A case-control study. J Am Coll Cardiol 45 (2005) 1753-1756
66. Kastrati A., von Beckerath N., Joost A., Pogatsa-Murray G., Gorchakova O., and Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110 (2004) 1916-1919
67. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronay intervention. Results from the Armyda-2 study. Circulation 111 (2005) 2099-2106
68. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
69. Brandt J.T., Payne C.D., Weerakkody G., Behounek B.D., Naganuma H., Jakubowski J.A., Wiviott S.D., and Winters K.J. Superior responder rate for inhibition of platelet aggregation with a 60 mg loading dose of prasugrel (CS-747, LY640315) compared with a 300 mg loading dose of clopidogrel. J Am Coll Cardiol 45 Suppl. A (2005) 87A [abstract]
70. Wiviot S.D., Antmann E.M., Winters K.J., Weerakkody G., Murphy S., Behounek B., Carney R., Lazzam C., McKayr R., McCabe C., Braunwald E., and for the JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 Trial. Circulation 111 (2005) 3366-3373
71. Greenbaum A., Grines C., Bittl J., Becker R., Kereiakes D., Gilchrist I., Clegg J., Stankowski J., Grogan D., and Harrington R. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial. Am Heart J 151 (2006) 689e1-689e10
72. Jacobsson F., Dellborg M., Swahn E., and Wallentin L. Tolerance and safety of cangrelor, a novel purine receptor antagonist, used as platelet aggregation inhibitor in the acute coronary syndrome. J Am Coll Cardiol 35 Suppl. A (2000) 343A
73. Storey R.F., Oldroyd K.G., and Wilcox R.G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85 (2001) 401-407
74. Park S.W., Lee C.W., Kim H.S., Lee H.J., Park H.K., Hong M.K., Kim J.J., and Park S.J. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 84 (1999) 511-514
75. Lee S.W., Park S.W., Hong M.K., Lee C., Kim Y., Park J., Kang S., Han K., Kim J., and Park S. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol 95 (2005) 859-862
76. Lee S.W., Park S.W., Hong M.K., Kim Y.-H., Lee B.-K., Song J.-M., Han K.-H., Lee C.W., Kang D.-H., Song J.-K., Kim J.-J., and Park S.-J. Triple versus dual antiplatelet therapy after coronary stenting. Impact on stent thrombosis. J Am Coll Cardiol 46 (2005) 1833-1837